Amgen — May 1, 2025 release

$Billions, except shares Q1 ’25 Q1 ’24 YOY Δ Operating Cash Flow $ 1.4  $ 0.7  $ 0.7  Capital Expenditures $ 0.4  $ 0.2  $ 0.2  Free Cash Flow $ 1.0  $ 0.5  $ 0.5  Dividends Paid $ 1.3  $ 1.2  $ 0.1  Share Repurchases $ —  $ —  $ —  Average Diluted Shares (millions) 541  536  5  Note: Numbers may not add due to rounding AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Page 7 $Billions 3/31/25 12/31/24 YTD Δ Cash and Cash Equivalents $ 8.8  $ 12.0  $ (3.2) Debt Outstanding $ 57.4  $ 60.1  $ (2.7) Note: Numbers may not add due to rounding 2025 Guidance For the full year 2025, the Company expects: • Total revenues in the range of $34.3 billion to $35.7 billion. • On a GAAP basis, EPS in the range of $12.21 to $13.46, and a tax rate in the range of 11.0% to 12.5%. • On a non-GAAP basis, EPS in the range of $20.00 to $21.20, and a tax rate in the range of 14.5% to 16.0%. • Capital expenditures to be approximately $2.3 billion. • Share repurchases not to exceed $500 million. This guidance includes the estimated impact of implemented tariffs, but does not account for any tariffs that could be implemented in the future, including potential sector-specific tariffs. First Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a differentiated peptide-antibody conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the gastric inhibitory polypeptide receptor (GIPR). • MARITIME-1, a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of maridebart cafraglutide is enrolling adults living with overweight or obesity, without Type 2 diabetes mellitus. • MARITIME-2, a Phase 3 randomized, double-blind, placebo-controlled stud